By High Peptides Research Team · August 21, 2026

GLP-1 · Discontinuation

Stopping Retatrutide: the rebound truth

📄 6 PubMed citations

A viral protocol claims a slow taper plus a peptide stack lets you keep the weight off after retatrutide. The withdrawal trials tell a different story — here is what the evidence actually supports.

🔬 Unlike threads selling a "taper stack," this page separates what is proven — that regain is a class-wide, hormone-driven effect — from what is marketing: that any taper schedule or peptide add-on has been shown to prevent it. No retatrutide-specific withdrawal trial has been published yet, so we reason from the semaglutide and tirzepatide withdrawal RCTs, and say so plainly.

11.6 pts

of lost weight regained a year after stopping semaglutide (of 17.3% lost) — STEP 1 extension

14%

body-weight regained after switching off tirzepatide over the next year — SURMOUNT-4

published retatrutide-specific withdrawal / rebound trials to date

Mechanism of Action

How It Works

🧬

Appetite hormones snap back

When the drug leaves, the biology it was suppressing returns. After weight loss, ghrelin (hunger) stays elevated and leptin, PYY and CCK (fullness) stay blunted for at least a year (Sumithran 2011). Retatrutide masks this drive while dosed; stopping removes the mask.

⚖️

It is the drug, not the taper

In randomized withdrawal trials, people switched to placebo regained weight while those who continued the drug kept losing — regardless of how the dose ended. STEP 4: +6.9% off-drug vs -7.9% continued. SURMOUNT-4: +14.0% vs -5.5%.

📉

Cardiometabolic gains revert

The STEP 1 extension found blood-pressure, lipid and glycemic improvements drifted back toward baseline as weight returned. The benefits track current body weight, not a lasting memory of the drug.

❓

No retatrutide withdrawal data yet

Retatrutide is still in phase 3; no published trial has tested stopping it. Its rebound profile is inferred from the GLP-1/GIP/glucagon class — the honest best-available guide, and not a reason to trust an untested taper protocol.

Data

What the Data Shows

Tirzepatide → placebo (SURMOUNT-4, wk36–88)

regain

+14.0%

Semaglutide stopped (STEP 1 ext, to wk120)

≈2/3 of loss regained

+11.6 pts

Semaglutide → placebo (STEP 4, wk20–68)

regain

+6.9%

Tirzepatide continued (SURMOUNT-4)

further loss

-5.5%

Semaglutide continued (STEP 4)

further loss

-7.9%

Bottom Line

Key Takeaways

✅ What We Know

Weight regain after stopping GLP-1–class drugs (semaglutide, tirzepatide) is consistently documented in randomized withdrawal trials.
The driver is physiology: appetite-regulating hormones that favor regain persist for at least a year after weight loss (Sumithran 2011).
In head-to-head RCTs, continuing the drug — not how the dose was tapered — is what maintained the loss (STEP 4, SURMOUNT-4).
Cardiometabolic improvements (blood pressure, lipids, glycemia) largely revert as weight returns (STEP 1 extension).
Retatrutide produces large loss (up to ~24.2% at 48 weeks in its phase 2 trial), so there is a lot of weight that can potentially come back.

⚠️ What We Don't Know

No published trial has tested stopping retatrutide, so its exact rebound curve and timing are unknown.
No RCT shows that tapering the dose down (vs stopping) prevents weight regain — tapering is used to limit GI side effects, not to lock in results.
No controlled evidence shows tesamorelin, MOTS-c, 5-amino-1MQ or similar "bridge" peptides prevent post-GLP-1 rebound.
Whether a maintenance dose, structured lifestyle change, or resistance training fully prevents long-term regain is not settled.
How much of retatrutide’s loss is regained, and how fast, will only be known once withdrawal data are published.

FAQ

Frequently Asked Questions

Why do you gain weight back after stopping retatrutide?

Because the drug was suppressing appetite biology that returns once it is gone. After weight loss, hunger hormones like ghrelin stay elevated and fullness signals stay blunted for at least a year, so appetite and food intake climb. In semaglutide and tirzepatide withdrawal trials, most participants regained a large share of the weight they had lost.

Does tapering off retatrutide prevent rebound?

There is no clinical evidence that slowly tapering the dose prevents weight regain. Tapering is commonly used to reduce nausea and other GI side effects, but the withdrawal RCTs (STEP 4, SURMOUNT-4) show regain happens once drug exposure ends, regardless of how treatment is stopped.

Do peptides like tesamorelin or MOTS-c stop GLP-1 rebound?

No controlled trial has shown that any "bridge" peptide stack prevents post-GLP-1 weight regain. These compounds have their own separate research contexts; using them specifically to hold off rebound is speculative and unproven, not an evidence-based protocol.

How much weight do people regain after stopping GLP-1 drugs?

In the STEP 1 extension, semaglutide users regained about two-thirds of their lost weight a year after stopping (11.6 of 17.3 percentage points). In SURMOUNT-4, people switched off tirzepatide regained about 14% of body weight over the following year, while those who continued kept losing.

Is there a retatrutide-specific rebound study?

Not yet. Retatrutide is still in phase 3 and no withdrawal trial has been published. Its rebound profile is currently inferred from semaglutide and tirzepatide, the closest well-studied drugs in the same incretin class.

🔬 Research-Grade Source

Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.

Browse Swiss Chems →

Code HIGHPEP10 — 10% off regular-priced items

Affiliate links — support HighPeptides at no extra cost.